Daniel Chung

Dr. Chung is the Ophthalmic Lead for Spark Therapeutics. Prior to joining Spark Therapeutics, he was a senior investigator at the FM Kirby Center for Molecular Ophthalmology at the Scheie Eye Institute at the Perelman School of Medicine of the University of Pennsylvania, working in retinal gene therapy and transfer. Concurrently, he served as the scientific advisor on the RPE65 gene therapy study team at the Children’s Hospital of Philadelphia (CHOP). Dr. Chung earned his medical degree from the New York Institute of Technology College of Osteopathic Medicine and completed his residency in Akron, Ohio. He then completed fellowships in pediatric ophthalmology and ocular genetics research at the Cole Eye Institute at the Cleveland Clinic, with additional training in retinal gene therapy at the National Eye Institute in Bethesda, MD. In his current duties, he continues to be connected to the RPE65 gene therapy trial, as Spark Therapeutics is now the sponsor. As the global ophthalmic lead, he works in the areas of medical affairs, clinical development and operations, and research and development.